bluebird bio (NASDAQ:BLUE) Price Target Increased to $12.00 by Analysts at Bank of America
bluebird bio (NASDAQ:BLUE – Free Report) had its price objective boosted by Bank of America from $11.00 to $12.00 in a research note issued to investors on Monday morning, Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently issued reports on the stock. […]
More Stories
Saks Fifth Avenue to Close Store in San Francisco’s Union Square
By Jill McLaughlin Luxury department chain Saks Fifth Avenue confirmed April 25 that it will close its Union Square location...
Open Hip Joints to Avoid Knee Pain in Sitting Cross-Legged Positions
By Amber Yang Many people use meditation to relieve stress. However, if you choose to meditate while sitting in the...
Trump Says He Hopes Ukraine Will Immediately Sign Minerals Deal
By Tom Ozimek U.S. President Donald Trump said on Friday that Ukraine hasn’t signed a long-delayed rare earths agreement that...
Politicians and Pilgrims Alike Gather for Pope Francis’s Funeral
By T.J. Muscaro The sun rose high over a packed St. Peter’s Square on the morning of April 26 as...
Elevance Health (NYSE:ELV) Earns “Overweight” Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Elevance Health (NYSE:ELV – Free Report) in a research note released...
Elevance Health’s (ELV) Outperform Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada reiterated their outperform rating on shares of Elevance Health (NYSE:ELV – Free Report) in a research...